Ofatumumab – the first fully human monoclonal antibody approved for the treatment of multiple sclerosis

Abstract

Currently, more than 15 molecules are already approved for the treatment of multiple sclerosis, and sometimes physicians encounter problems selecting a drug for therapy when considering patients with the initial equivalent characteristics. When selecting a drug, it is important to consider not only the efficacy and safety of the drug, but also the possibility of further therapy after discontinuation of the initially selected drug. This paper discusses the results of clinical trials on the efficacy and safety of ofatumumab and its potential advantages over other anti-CD20 agents.

Keywords

• multiple sclerosis
• ofatumumab
• monoclonal antibody
• anti-cd20